Source: Healio News
The manufacturer of a drug that received FDA approval earlier this year for treatment of multiple myeloma has pulled the therapy from the U.S. market.
The decision came 3 months after the FDA alerted health care providers and patients about clinical trial results that showed increased mortality risk among patients who received the agent.
Melphalan flufenamide (Pepaxto, Oncopeptides) — an anticancer peptide-drug conjugate — uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound.
The FDA in February granted accelerated approval to the